Managing diabetic nephropathy

Practitioner

Volumn 249, Issue 1666, 2005, Pages 9-17

  Maxwell, Peter ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG SAFETY; GLOMERULUS; HEMODIALYSIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 12344289688     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853
3. Cowie CC, Port FK, Wolfe RA et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-1079
4. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:61-72
5. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
6. Parving H-H, Andersen AR, Smidt UM et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987;294:1443-1447
7. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279
8. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-234
9. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Eng J Med 2004;351:1941-1951
10. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462
11. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
12. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
13. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med 2004;351:1952-1961
14. Strippoli GF, Craig M, Decks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J 2004;329:828-831
15. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. Br Med J 2004;329:1248-1249
16. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004;328:634-640
17. Arauz-Pacheco C, Parrott MA, Raskin P for the American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S65-67
18. Scott LJ, Warram JH, Hanna LS et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001;50:2842-2849
19. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994;45:S125-131
20. Tonolo G, Ciccarese M, Brizzi P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-1895